Best diabetic macular oedema drugs ‘not cost-effective’

Resource utilisation data from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial show that the most efficacious drug for diabetic macular oedema, aflibercept, is not cost-effective relative to repackaged bevacizumab.
Source: MedWire News - Category: Consumer Health News Tags: Diabetes Source Type: news